Anti-C9 antibody [EPR11232],Abcam,AB168345

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

IP, WB, IHC-P

Platform ID

BAB298712165

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NameAnti-C9 antibody [EPR11232]
Cat. No.AB168345
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationIP, WB, IHC-P
ClonalityMonoclonal
Clone NumberEPR11232
Concentration0.114 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells (PubMed : 26841934, PubMed : 9212048, PubMed : 9634479). C9 is the pore-forming subunit of the MAC (PubMed : 26841934, PubMed : 30111885, PubMed : 4055801). See full target information C9

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.